4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System. This study will use an \"integrated consent model\" that involves \"oral consent\" rather than a written informed consent writing process as the study is comparing standard schedules and not a new administration schedule.
Epistemonikos ID: 42f0da8bca1d91c057be345cc86a8813a7332c1c
First added on: May 12, 2024